



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/915,263	07/27/2001	Jing Wu	002010-593	7971
21839	7590 04/07/2004	EXAMINER		
	ANE SWECKER & MA	KIFLE, E	KIFLE, BRUCK	
100.0	CE BOX 1404 MA, VA 22313-1404	ART UNIT	PAPER NUMBER	
			1624	
			DATE MAILED: 04/07/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
	•	09/915,263	WU ET AL.			
Office Act	ion Summary	Examiner	Art Unit			
		Bruck Kifle, Ph.D.	1624			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ Responsive to communication(s) filed on <i>04 February 2004</i> .						
2a)⊠ This action is F		action is non-final.				
, — · · ·						
Disposition of Claims						
4a) Of the above 5) ☐ Claim(s) 6) ☑ Claim(s) <u>118-12</u> 7) ☐ Claim(s)		wn from consideration.				
Application Papers	•					
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
•	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
· · · · · · · · · · · · · · · · · · ·						
Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)	-4 (DTO 000)		n/ (DTO 442)			
· <u> </u>	Patent Drawing Review (PTO-948) tatement(s) (PTO-1449 or PTO/SB/08	4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:				

Application/Control Number: 09/915,263

Art Unit: 1624

Applicant's amendments and remarks filed 02/04/2004 have been entered. Claims 118-120 are still pending in this application.

## Claim Rejections - 35 USC § 112

Claims 118-120 are again rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification is not adequately enabling for the scope of the compounds embraced by the claims. The basis of this rejection is the same as given in the previous office action and is incorporated herein fully by reference. Pharmacological activity in general is a very unpredictable area. Note that in cases involving physiological activity such as the instant case, "the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved". See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).

Also, see In re Surrey 151 USPQ 724, regarding sufficiency of a disclosure for a Markush group, and MPEP 2164.03 for enablement requirements in cases directed to structure-sensitive arts such as the instant pharmaceutical arts. Note in Surrey, in which testing done on a group of homogeneous compounds having the same core was deemed NOT sufficient to support claims to various hetero groups of a much narrower range than is being claimed herein and located at only one position in the formula. See MPEP 2164.03. The instant scope is enormous, in the billions of compounds. An Applicant is not entitled to a claim for the use of a large group of compounds merely on the basis of a showing that a selected few are useful and a general suggestion of a similar utility in the others.

Application/Control Number: 09/915,263

Art Unit: 1624

## Provisos

There are provisos in the claims that exclude compounds embraced by the claims. If these provisos are present to avoid prior art, applicants are urgently requested to point out these references to the examiner because of their importance in the examination of the claims.

Applicants have still not respond to this query and request clarification. A detailed explanation, however, was given in the previous office action.

Regarding the requirement to maintain a clear line of demarcation, Applicants need to say whether equivalent US applications of WO 99/67221, WO 98/28268 and WO 2001/034571 exist and to maintain a clear line of demarcation between the corresponding US applications and the instant application. See MPEP § 822. Applicants need to point out what the differences in scopes are.

In re Fressola, 22 USPQ 2nd 1828, indicates that the Examiner may reject for Applicants failure to follow a Rule.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

Application/Control Number: 09/915,263

Art Unit: 1624

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle, Ph.D. whose telephone number is 571-272-0668. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund J. Shah can be reached on 571-272-0674. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Bruck Kifle, Ph.Ď. Primary Examiner Art Unit 1624

BK April 2, 2004